Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for Immune Activation in HIV (Gutsy)
NCT06022406Phase 2Completed
- Start
- Jul 2024
- Primary completion
- Aug 2025
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Fecal Microbiota Transplantation Capsule in human immunodeficiency virus type 1 infection (HIV-1) (2 arms). Primary endpoint: Regenerating Islet Derived protein 3 alpha at 12 weeks. Started Jul 2024; status: completed.
02
Drugs
Fecal Microbiota Transplantation Capsule
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT06022406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06022406.